Form 8-K - Current report:
SEC Accession No. 0001628280-21-015854
Filing Date
2021-08-05
Accepted
2021-08-05 16:11:33
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20210805.htm   iXBRL 8-K 38062
2 EX-99.1 exhibit991_q22021pressrele.htm EX-99.1 118108
6 GRAPHIC aurinalogoa.jpg GRAPHIC 11010
  Complete submission text file 0001628280-21-015854.txt   318665

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20210805.xsd EX-101.SCH 1942
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20210805_lab.xml EX-101.LAB 23970
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20210805_pre.xml EX-101.PRE 12668
7 EXTRACTED XBRL INSTANCE DOCUMENT auph-20210805_htm.xml XML 11099
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 211148284
SIC: 2834 Pharmaceutical Preparations